Clinical Trials

235 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-03-13

MoonRISe-1

Phase 3 Recruiting

641 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-03-13

MoonRISe-3

Phase 3 Recruiting

220 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07309445 2026-03-13

Nova-sTAR

Recruiting

150 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07206225 2026-03-11

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Phase 1 Recruiting

294 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06637423 2026-02-19

TroFuse-027

32 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05951179 2026-01-27

ADVANCED-2

131 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04752722 2026-01-26

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

350 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT07283835 2026-01-21

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

16 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT02660645 2025-12-18

BLCCR

Recruiting

4,400 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03945162 2025-11-24

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

90 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02138734 2025-10-16

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

596 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT06663137 2025-06-13

HGNMIBC

70 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06186414 2025-01-15

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

Phase 1 Recruiting

152 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06241755 2024-02-05

Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Recruiting

412 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05943379 2023-07-13

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

85 enrolled